First Analysis Initiates Coverage on Catalent (CTLT)
Stock analysts at First Analysis assumed coverage on shares of Catalent (NYSE:CTLT) in a research note issued on Friday. The firm set an “equal weight” rating on the stock.
CTLT has been the subject of several other reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Catalent in a report on Monday, October 23rd. Zacks Investment Research lowered Catalent from a “buy” rating to a “hold” rating in a report on Friday, November 3rd. BidaskClub raised Catalent from a “hold” rating to a “buy” rating in a report on Thursday, October 5th. ValuEngine raised Catalent from a “hold” rating to a “buy” rating in a report on Thursday, September 7th. Finally, Piper Jaffray Companies upped their price objective on Catalent from $45.00 to $50.00 and gave the company an “overweight” rating in a research note on Tuesday, November 7th. One analyst has rated the stock with a sell rating, five have given a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $44.44.
Shares of Catalent (NYSE CTLT) traded down $0.57 during trading on Friday, reaching $41.78. The company had a trading volume of 650,300 shares, compared to its average volume of 834,533. Catalent has a twelve month low of $25.51 and a twelve month high of $43.39. The company has a market cap of $5,530.00, a price-to-earnings ratio of 48.58, a price-to-earnings-growth ratio of 2.72 and a beta of 1.41. The company has a debt-to-equity ratio of 2.01, a current ratio of 2.91 and a quick ratio of 2.49.
Catalent (NYSE:CTLT) last issued its quarterly earnings data on Monday, November 6th. The company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.01. The firm had revenue of $543.90 million during the quarter, compared to analyst estimates of $490.75 million. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The company’s revenue for the quarter was up 23.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.16 EPS. sell-side analysts predict that Catalent will post 1.46 earnings per share for the current fiscal year.
In related news, Director Uwe Roehrhoff acquired 7,500 shares of the stock in a transaction on Tuesday, November 21st. The stock was acquired at an average cost of $39.22 per share, for a total transaction of $294,150.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John R. Chiminski sold 181,458 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total transaction of $7,189,365.96. The disclosure for this sale can be found here. Corporate insiders own 1.70% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio increased its position in shares of Catalent by 1,441.4% during the third quarter. Public Employees Retirement System of Ohio now owns 41,156 shares of the company’s stock valued at $1,643,000 after acquiring an additional 38,486 shares in the last quarter. GSA Capital Partners LLP increased its position in shares of Catalent by 59.0% during the third quarter. GSA Capital Partners LLP now owns 52,972 shares of the company’s stock valued at $2,115,000 after acquiring an additional 19,661 shares in the last quarter. Iguana Healthcare Management LLC bought a new stake in shares of Catalent during the third quarter valued at approximately $1,198,000. Colony Group LLC bought a new stake in shares of Catalent during the third quarter valued at approximately $2,543,000. Finally, Neuberger Berman Group LLC increased its position in shares of Catalent by 77.3% during the third quarter. Neuberger Berman Group LLC now owns 23,025 shares of the company’s stock valued at $919,000 after acquiring an additional 10,036 shares in the last quarter. Hedge funds and other institutional investors own 99.37% of the company’s stock.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.